Anti Inflammatory News and Research

RSS

Unintended direct conflict between pharmaceutical marketing and public health

Drugs that pharmaceutical companies market most aggressively to physicians and patients tend to offer less benefit and more harm to most patients - a phenomenon described as the "inverse benefit law" in a paper from the University of Texas Medical Branch at Galveston.

14 Jan 2011

NSAIDs raise risk of heart disease: Study

A new study published online in the British Medical Journal explores the relative safety of non-steroidal anti-inflammatory medications (NSAIDs), commonly used to treat joint and muscle aches and pain and concludes that NSAIDs significantly increase the risk of cardiovascular events in patients who take them regularly.

12 Jan 2011

Patients who consume painkillers may face cardiovascular risk

The drugs include traditional non-steroidal anti-inflammatory drugs as well as new generation anti-inflammatory drugs, known as COX-2 inhibitors. The researchers say that doctors and patients need to be aware that prescription of any anti-inflammatory drug needs to take cardiovascular risk into account.

12 Jan 2011

Study: Protein that plays a key role in some antioxidant therapies can promote atherosclerosis

UCLA researchers have found that a protein that plays an important role in some antioxidant therapies may not be as effective due to additional mechanisms that cause it to promote atherosclerosis, or clogging of the arteries.

11 Jan 2011

Pennsaid fourth quarter prescriptions increase 20% sequentially

Nuvo Research Inc., a specialty pharmaceutical company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced it will be meeting with several U.S. investment bankers, analysts and fund managers during J.P. Morgan's 29th annual Healthcare Conference held from January 10th to January 13th, 2011, in San Francisco, California.

10 Jan 2011

Iroko reports positive results from Phase I clinical study of nanotechnology based unique formulation of naproxen

Iroko Pharmaceuticals, LLC today reported the results of the Phase I clinical study of its unique formulation of naproxen, a widely used pain medication, using proprietary, patent protected nanotechnology.

7 Jan 2011

Virdante Pharmaceuticals receives US key patent for Sialic Switch technology

Virdante Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office has granted a key patent that supports the Company's "Sialic Switch" technology for improving the anti-inflammatory activity of antibody-based drugs to treat autoimmune and inflammatory disorders.

7 Jan 2011

Insite Vision announces completion of patient enrollment in ISV-303 Phase 1/2 trial for post surgical ocular pain, inflammation

InSite Vision Incorporated, a company developing novel ophthalmic therapeutics, today announced that patient enrollment was recently completed in the company's Phase 1/2 clinical trial of ISV-303, a novel compound being developed to reduce the pain and inflammation associated with ocular surgery.

6 Jan 2011

Vaccinex receives FDA clearance to initiate VX15/2503 Phase 1 clinical trial in advanced solid tumors

Vaccinex, Inc. announced today that it has received clearance from FDA and will initiate a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of therapeutic antibody candidate VX15/2503 in cancer patients with advanced solid tumors.

5 Jan 2011

Fundamental similarities in response to wasp infection and blood cancer development

Tiny parasitoid wasps can play an important role in controlling the populations of other insect species by laying their eggs inside the larvae of these species. A newly hatched wasp gradually eats the host alive and takes over its body.

4 Jan 2011

Immunitor reports positive safety imm01 clinical trial against tuberculosis

Immune Network Ltd., advises that Immunitor has published data from the first half of the 120-patient imm01 clinical trial of its V5 immunomodulator product against tuberculosis, including difficult-to-treat forms of the disease.

30 Dec 2010

Loyola University offers tips to avoid the misery of New Year's hangover

Exercise and B vitamins can help cure a hangover, but coffee won't help. These are among the tips that Loyola University Health System family physician Dr. Aaron Michelfelder offers to avoid the misery of a New Year's hangover.

30 Dec 2010

Positive results from OMS201 Phase 1/2 trial in patients undergoing urologic procedures

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced results from the Phase 1/2 clinical trial of OMS201, the Company's urological PharmacoSurgery™ product candidate.

29 Dec 2010

Transition, Elan to modify collaboration agreement for development, commercialization of ELND005

Transition Therapeutics Inc. today announced that the Company and Elan Corporation, plc have mutually agreed to modify their collaboration agreement for the development and commercialization of ELND005.

27 Dec 2010

Quercetin and resveratrol may play an important role in inflammation and insulin resistance

A study was carried out to examine the extent to which quercetin and trans-resveratrol (RSV) prevented inflammation or insulin resistance in primary cultures of human adipocytes treated with tumor necrosis factor-a (TNF-a)-an inflammatory cytokine elevated in the plasma and adipose tissue of obese, diabetic individuals. Cultures of human adipocytes were pretreated with quercetin and trans-RSV followed by treatment with TNF-a. Subsequently, gene and protein markers of inflammation and insulin resistance were measured.

24 Dec 2010

Millennia compiles data on 100 wounds treated with Cytomedix AutoloGel System

Cytomedix, Inc. a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced that its Japanese partner, Millennia Holdings, Inc. ("Millennia"), has compiled data on 100 wounds treated with the Company's AutoloGel™ System, and will use this initial data to support its regulatory and reimbursement filings in Japan. The full data set is expected to be released through presentations at scientific and medical meetings and through publication in a peer-reviewed journal.

22 Dec 2010

Altering balance among immune system cells could hold potential for T2D-associated inflammation treatment

Researchers from Boston University School of Medicine (BUSM) have demonstrated that certain T cells require input from monocytes in order to maintain their pro-inflammatory response in people with type 2 diabetes (T2D). The study also showed, for the first time, how a loss in homeostasis in this group of T cells most likely promotes chronic inflammation associated with T2D.

22 Dec 2010

Spirulina dietary supplement may provide clinical benefits for ALS patients

Nutritional supplementation with Spirulina, a nutrient-rich, blue-green algae, appeared to provide neuroprotective support for dying motor neurons in a mouse model of amyotrophic lateral sclerosis, also known as Lou Gehrig's disease, University of South Florida neuroscientists have found.

21 Dec 2010

Training more effective than anti-inflammatory drugs in treating tennis elbow

Training and ergonomic advice are more effective than anti-inflammatory drugs and cortisone injections in treating tennis elbow, and give fewer side effects. This is the conclusion of a thesis presented at the University of Gothenburg, Sweden.

21 Dec 2010

New research sheds light on complex regulatory pathways for effective innate immune system

New research by scientists at the University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences reveals that the immune system has an effective backup plan to protect the body from infection when the "master regulator" of the body's innate immune system fails.

21 Dec 2010

Anti Inflammatory News and Research

Unintended direct conflict between pharmaceutical marketing and public health

NSAIDs raise risk of heart disease: Study

Patients who consume painkillers may face cardiovascular risk

Study: Protein that plays a key role in some antioxidant therapies can promote atherosclerosis

Pennsaid fourth quarter prescriptions increase 20% sequentially

Iroko reports positive results from Phase I clinical study of nanotechnology based unique formulation of naproxen

Virdante Pharmaceuticals receives US key patent for Sialic Switch technology

Insite Vision announces completion of patient enrollment in ISV-303 Phase 1/2 trial for post surgical ocular pain, inflammation

Vaccinex receives FDA clearance to initiate VX15/2503 Phase 1 clinical trial in advanced solid tumors

Fundamental similarities in response to wasp infection and blood cancer development

Immunitor reports positive safety imm01 clinical trial against tuberculosis

Loyola University offers tips to avoid the misery of New Year's hangover

Positive results from OMS201 Phase 1/2 trial in patients undergoing urologic procedures

Transition, Elan to modify collaboration agreement for development, commercialization of ELND005

Quercetin and resveratrol may play an important role in inflammation and insulin resistance

Millennia compiles data on 100 wounds treated with Cytomedix AutoloGel System

Altering balance among immune system cells could hold potential for T2D-associated inflammation treatment

Spirulina dietary supplement may provide clinical benefits for ALS patients

Training more effective than anti-inflammatory drugs in treating tennis elbow

New research sheds light on complex regulatory pathways for effective innate immune system

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News